Cargando…
Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes
(1) Background: Oral semaglutide represents the first oral GLP-1 RA approved for the treatment of type 2 diabetes mellitus (T2DM). This real-world retrospective study aimed at evaluating its effectiveness and tolerability in the treatment of patients with T2DM when patients switched from a glucose-l...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532177/ https://www.ncbi.nlm.nih.gov/pubmed/37762991 http://dx.doi.org/10.3390/jcm12186052 |
_version_ | 1785111894481174528 |
---|---|
author | Candido, Riccardo Gaiotti, Sara Giudici, Fabiola Toffoli, Barbara De Luca, Federica Velardi, Valerio Petrucco, Alessandra Gottardi, Chiara Manca, Elena Buda, Iris Fabris, Bruno Bernardi, Stella |
author_facet | Candido, Riccardo Gaiotti, Sara Giudici, Fabiola Toffoli, Barbara De Luca, Federica Velardi, Valerio Petrucco, Alessandra Gottardi, Chiara Manca, Elena Buda, Iris Fabris, Bruno Bernardi, Stella |
author_sort | Candido, Riccardo |
collection | PubMed |
description | (1) Background: Oral semaglutide represents the first oral GLP-1 RA approved for the treatment of type 2 diabetes mellitus (T2DM). This real-world retrospective study aimed at evaluating its effectiveness and tolerability in the treatment of patients with T2DM when patients switched from a glucose-lowering agent to it and when it was added to the usual therapy. (2) Methods: Adult patients with T2DM taking oral semaglutide and followed in the ASUGI Diabetes Center were identified with the use of electronic medical records between October 2022 and May 2023. (3) Results: A total of 129 patients were recruited. The median follow-up was 6 months. Be it as a switchover or as an add-on therapy, oral semaglutide significantly reduced HbA1c and BMI. Switching from DPPIV inhibitors to oral semaglutide was associated with a significant reduction in HbA1c and BMI, switching from SGLT2 inhibitors was associated with a significant reduction in HbA1c, and switching from sulphonylureas was associated with a significant reduction in BMI. The median HbA1c change was associated with baseline HbA1c. SBP significantly decreased in the add-on group. Oral semaglutide was well tolerated. (4) Conclusions: This study shows that in the real-world setting, oral semaglutide is effective and safe as a switchover or as an add-on therapy for the treatment of T2DM. |
format | Online Article Text |
id | pubmed-10532177 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105321772023-09-28 Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes Candido, Riccardo Gaiotti, Sara Giudici, Fabiola Toffoli, Barbara De Luca, Federica Velardi, Valerio Petrucco, Alessandra Gottardi, Chiara Manca, Elena Buda, Iris Fabris, Bruno Bernardi, Stella J Clin Med Article (1) Background: Oral semaglutide represents the first oral GLP-1 RA approved for the treatment of type 2 diabetes mellitus (T2DM). This real-world retrospective study aimed at evaluating its effectiveness and tolerability in the treatment of patients with T2DM when patients switched from a glucose-lowering agent to it and when it was added to the usual therapy. (2) Methods: Adult patients with T2DM taking oral semaglutide and followed in the ASUGI Diabetes Center were identified with the use of electronic medical records between October 2022 and May 2023. (3) Results: A total of 129 patients were recruited. The median follow-up was 6 months. Be it as a switchover or as an add-on therapy, oral semaglutide significantly reduced HbA1c and BMI. Switching from DPPIV inhibitors to oral semaglutide was associated with a significant reduction in HbA1c and BMI, switching from SGLT2 inhibitors was associated with a significant reduction in HbA1c, and switching from sulphonylureas was associated with a significant reduction in BMI. The median HbA1c change was associated with baseline HbA1c. SBP significantly decreased in the add-on group. Oral semaglutide was well tolerated. (4) Conclusions: This study shows that in the real-world setting, oral semaglutide is effective and safe as a switchover or as an add-on therapy for the treatment of T2DM. MDPI 2023-09-19 /pmc/articles/PMC10532177/ /pubmed/37762991 http://dx.doi.org/10.3390/jcm12186052 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Candido, Riccardo Gaiotti, Sara Giudici, Fabiola Toffoli, Barbara De Luca, Federica Velardi, Valerio Petrucco, Alessandra Gottardi, Chiara Manca, Elena Buda, Iris Fabris, Bruno Bernardi, Stella Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes |
title | Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes |
title_full | Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes |
title_fullStr | Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes |
title_full_unstemmed | Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes |
title_short | Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes |
title_sort | real-world retrospective study into the effects of oral semaglutide (as a switchover or add-on therapy) in type 2 diabetes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532177/ https://www.ncbi.nlm.nih.gov/pubmed/37762991 http://dx.doi.org/10.3390/jcm12186052 |
work_keys_str_mv | AT candidoriccardo realworldretrospectivestudyintotheeffectsoforalsemaglutideasaswitchoveroraddontherapyintype2diabetes AT gaiottisara realworldretrospectivestudyintotheeffectsoforalsemaglutideasaswitchoveroraddontherapyintype2diabetes AT giudicifabiola realworldretrospectivestudyintotheeffectsoforalsemaglutideasaswitchoveroraddontherapyintype2diabetes AT toffolibarbara realworldretrospectivestudyintotheeffectsoforalsemaglutideasaswitchoveroraddontherapyintype2diabetes AT delucafederica realworldretrospectivestudyintotheeffectsoforalsemaglutideasaswitchoveroraddontherapyintype2diabetes AT velardivalerio realworldretrospectivestudyintotheeffectsoforalsemaglutideasaswitchoveroraddontherapyintype2diabetes AT petruccoalessandra realworldretrospectivestudyintotheeffectsoforalsemaglutideasaswitchoveroraddontherapyintype2diabetes AT gottardichiara realworldretrospectivestudyintotheeffectsoforalsemaglutideasaswitchoveroraddontherapyintype2diabetes AT mancaelena realworldretrospectivestudyintotheeffectsoforalsemaglutideasaswitchoveroraddontherapyintype2diabetes AT budairis realworldretrospectivestudyintotheeffectsoforalsemaglutideasaswitchoveroraddontherapyintype2diabetes AT fabrisbruno realworldretrospectivestudyintotheeffectsoforalsemaglutideasaswitchoveroraddontherapyintype2diabetes AT bernardistella realworldretrospectivestudyintotheeffectsoforalsemaglutideasaswitchoveroraddontherapyintype2diabetes |